PISCATAWAY, N.J. — Camber Pharmaceuticals is pleased to announce the addition of deferasirox oral oranules to its current portfolio.
Deferasirox oral oranules are indicated for the treatment of chronic iron overload (1) due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older, and (2) in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes exhibiting elevated liver and serum iron concentrations.
Deferasirox oral granules 180 mg and 360 mg sachets are available in 30 count cartons.
